Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

Evolving market access pathways for AI-enabled Medtech in Europe

Louise Maddison (Senior Consultant – Global Market Access, Mtech Access) explores the evolving market access landscape for AI-enabled Medtech, with a particular focus on the key European markets of France,...

Petauri Evidence

- PMLiVE

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

- PMLiVE

AstraZeneca shares ‘unprecedented’ survival results for Imfinzi/Imjudo regimen in liver cancer

Almost 900,000 new cases of liver cancer are diagnosed globally every year

- PMLiVE

Sanofi/Regeneron’s Dupixent receives FDA approval for adolescents with CRSwNP

Approximately 9,000 adolescents in the US are living with inadequately controlled cases of the chronic disease

- PMLiVE

Omnichannel – beyond MPUs and emails

By Paul Berressem

- PMLiVE

How to boost clinical trial access and make patients health-empowered

Clinical research is becoming more patient-centric, but there's still more that needs to be done to make clinical trials available to everyone. This could include wider participation.

Cuttsy + Cuttsy

- PMLiVE

Medscape Education and Comprehensive Medical Mentoring Program Partner to Empower the Next Generation in Dermatology

In a significant stride toward fostering diversity and inclusivity in dermatology, Medscape Education and the Comprehensive Medical Mentoring Program (CMMP) have established a unique alliance to address critical gaps in...

Medscape Education

- PMLiVE

Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin condition occurs in 7.3% of adults in the US

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

- PMLiVE

Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types

Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes

- PMLiVE

Sanofi, RadioMedix and Orano Med partner to develop rare cancer therapy in deal worth €320m

AlphaMedix is currently being evaluated as a treatment for neuroendocrine tumours

- PMLiVE

GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults

The company said it will now progress the programme into late-stage clinical development

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links